Last updated:
4/30/2024
Years published: 2019, 2024
NORD gratefully acknowledges Lakshmi Nayak, MD, Director of the Center for CNS Lymphoma, Center for Neuro-Oncology, Dana-Farber Cancer Institute, for assistance in the preparation of this report.
Summary
A primary central nervous system lymphoma (PCNSL) is a type of cancer originating from immune cells known as lymphocytes (lymphoma) that develops in the brain and/or spinal cord (central nervous system; CNS). Around 1,500 patients are diagnosed each year in the United States. Older individuals and those with an impaired immune system (immunocompromised), especially those living with HIV/AIDS, are at an increased risk of developing a primary CNS lymphoma. PCNSL is an AIDS-defining illness, meaning that a HIV-positive individual with a PCNSL will be considered to have AIDS. The symptoms of PCNSL are similar to those of other brain tumors and can include arm and leg weakness, cognitive and behavioral changes, brain swelling, language deficits and vision changes. High-dose methotrexate (HD-MTX) based chemotherapy is the main treatment for PCNSL.
The potential symptoms of primary CNS lymphoma are varied and mostly depend on the location of the tumor. Symptoms typically develop over weeks (subacute).
Common signs and symptoms may include:
If specific structures within the brain (such as the pituitary gland and hypothalamus) are damaged, PCNSL can be associated with:
Involvement of the brainstem which connects the brain and the spinal cord can lead to:
Spinal cord involvement is rare in PCNSL. When the spinal cord is compressed and damaged (myelopathy) by a mass, affected individuals can have:
Other structures that can be compromised by a primary CNS lymphoma include the coverings of the brain (meninges) and the peripheral and cranial nerves (neurolymphomatosis). The latter can lead to:
PCNSL is a malignant tumor and can potentially spread to other sites outside the central nervous system, although systemic dissemination is rare. Systemic spread of PCNSL can lead to weight loss, fever and night sweats. Those symptoms are known as constitutional or B symptoms. Such symptoms may be present in patients with AIDS-related PCNSL even in the absence of systemic spread.
PCNSL most commonly occurs in individuals around age 65, but rare cases have also been described in children. AIDS-related PCNSL tends to develop in younger patients in their 40s. With proper treatment, primary CNS lymphoma regresses in around 85% of patients. However, relapse occurs in 50% of patients, most often within two years.
The average survival after a diagnosis of PCNSL is 44 months. Overall, 30% of affected individuals survive more than five years after diagnosis, and long-term survival is achieved in 15 to 20% of patients. Age under 60 years and high level of autonomy and functioning at the time of diagnosis are associated with increased survival, while HIV/AIDS and involvement of deep regions of the brain are associated with lower survival. Elevated blood levels of lactate dehydrogenase (LDH) and elevated protein concentration in the cerebrospinal fluid, both of which are usually measured during diagnostic workup, are also associated with lower survival.
Primary CNS lymphomas most often develop from the uncontrolled proliferation of cells derived from B lymphocytes (also known as B cells), which are a type of immune cell. More rarely, PCNSL can also develop from T lymphocytes (also known as T cells), but our understanding of prognosis and therapies for PCNSL is based on patients who specifically have primary diffuse large B-cell lymphoma of the CNS. The exact mechanism by which malignant lymphocytes invade the brain is not understood yet, but there are two main hypotheses: lymphocytes might be drawn to the CNS and then replicate and lead to a malignant tumor. Alternatively, already malignant lymphocytes might be drawn to the CNS via the expression of specific adhesion molecules that mediate traffic to the brain.
Several molecular processes are thought to be involved in the malignant transformation of cells of primary CNS lymphomas. These processes lead to uncontrolled cell proliferation and avoidance of destruction of malignant cells, notably by evasion of the immune system (which would normally destroy abnormal cells). Gain and loss of genetic material is also involved in the development of primary CNS lymphoma. The result of these genetic changes is to allow malignant cells to escape from regulation of the immune system and to proliferate, notably via amplification of a molecular pathway known as NF-κB. Silencing of tumor suppressor genes is also one of the mechanisms by which PCNSL develops.
In addition to the malignant cells themselves, the environment in which the tumor grows might also play a role in PCNSL development. The vasculature of the brain might be involved, as PCNSL cells tend to accumulate around blood vessels. Evidence also shows that the tumor cells and surrounding cells secrete B cell surviving factors (notably interleukin 4) and promote a local inflammatory response.
A feature of primary CNS lymphoma that is mostly identified in immunocompromised individuals (such as those living with HIV/AIDS) is the presence of genetic material of the Epstein-Barr virus (EBV; which is the virus involved in most cases of infectious mononucleosis). EBV infection in people who are immunocompromised is thought to lead to malignancy by the excessive activation of human cell growth factors, activation of viral cell growth factors and chronic stimulation of the immune system.
Primary central nervous system lymphoma constitutes 2-3% of all brain tumors and develops in around five individuals per million each year, for a total of approximately 1,500 new cases per year in the United States. PCNSL is slightly more common in males. The most common risk factor for the development of a primary CNS lymphoma is an impaired immune system (immunosuppression). This is notably the case of patients living with HIV/ AIDS, especially those who are not treated who have a high viral load and low CD4+ cell count. Other immunosuppressed patients include organ transplant recipients and individuals with congenital immunodeficiency syndromes. In fact, primary CNS lymphoma is the most common brain tumor in immunosuppressed patients. The other main risk factor for developing a PCNSL is age. Most immunocompetent patients are diagnosed around age 65, although cases of PCNSL have also been reported in children. AIDS-related PCNSL most often develops during the fifth decade of life (age 40-49). There has been an increase in the incidence of immunocompetent PCNSL, particularly in the elderly.
The diagnosis of primary CNS lymphoma is complex and requires a combination of patient history, physical examination, laboratory testing, medical imaging, as well as microscopic, cellular and genetic analysis of the tumor cells.
Initially, history from the patient and a physical examination performed by a physician might identify signs and symptoms that are suggestive of a brain lesion. If such signs and symptoms are identified, medical imaging of the brain is performed by computed tomography (CT) scan or magnetic resonance imaging (MRI). Imaging of the spine can also be performed if the symptoms suggest spinal involvement. While medical imaging can lead to suspicion of a primary CNS lymphoma, definitive diagnosis is only possible by analysis of the cells of the tumor. A brain biopsy is the preferred method to diagnose primary CNS lymphoma especially if the tumor is in an area where biopsy is safe to perform as this gives the quickest diagnosis. Alternatively, lumbar puncture to collect cerebrospinal fluid (CSF) or vitrectomy (removal of vitreous/eye fluid) can be considered if biopsy is not possible. A lumbar puncture, which is a procedure where a needle is placed in the spinal column of the patient to collect cerebrospinal fluid (CSF), is typically performed to look for the presence of tumor cells. Fluid from the eye (vitreous fluid) can also be collected for the same reason.
Once tumor cells are obtained, they can be analyzed in multiple ways to confirm the diagnosis of primary CNS lymphoma. Flow cytometry is a laboratory method that allows identification of cells based on their size, shape and the presence of specific markers. Immunohistochemistry can complement microscopic analysis by staining cells based on their origin. The DNA of tumor cells can also be analyzed to identify the presence of specific gene variants.
Clinical Testing and Workup
The diagnosis of primary CNS lymphoma is usually followed by an extensive workup to evaluate the severity and spread of the disease within the nervous system and to rule out systemic involvement. Patients are usually tested for HIV due to the association between HIV infection and PCNSL. A full eye examination with a slit lamp is performed to see if there is eye involvement, as this can occur even in the absence of visual symptoms. CSF is checked for the presence of malignant cells. The level of protein in CSF and of lactate dehydrogenase (LDH) in the blood can be measured. The CSF can also be tested for the presence of Epstein-Barr virus, which is associated with PCNSL in immunocompromised individuals. A full body CT or PET scan, a testicular ultrasound (in older male patients) and possibly a bone marrow biopsy are also part of the diagnostic workup and are useful to determine if other organs are involved. If a patient is found to have lymphoma outside of the brain, spinal cord, cerebrospinal fluid or eyes, then they will be diagnosed with a systemic lymphoma and the brain involvement is considered a secondary CNS lymphoma.
Many other general tests are also typically performed to evaluate the baseline health of the patient and to determine the best treatment options. These tests might include blood tests to look for blood cells (complete blood count) and level of different electrolytes (biochemical serum profile), cognitive function test, renal (kidney) function test, liver (hepatic) function tests and cardiac function tests.
Treatment & Management
The mainstay of treatment is based on chemotherapy, notably with high-dose methotrexate (HD-MTX). Leucovorin (folinic acid) is often added to prevent systemic and bone marrow toxicity from MTX. Depending on the patient, HD-MTX can be combined with other chemo-immunotherapeutic drugs such as alkylating agents, cytarabine and rituximab. Chemotherapy regimens also vary depending on the center where the patient is treated, as many experimental treatments are being investigated.
Most patients respond well to initial chemotherapy. After completion of initial chemotherapy, additional therapies such as high-dose chemotherapy with or without autologous stem cell transplant or whole brain radiation can be considered to reduce the risk of relapse. Autologous stem cell transplant is a medical procedure where healthy stem cells from a person’s own body are used to replace bone marrow cells damaged by chemotherapy. The combination of chemotherapy and standard-dose whole brain radiotherapy can increase the risk of neurocognitive deficits especially in elderly patients. As such, the choice of additional therapy depends on several factors such as age, overall medical condition, response to initial chemotherapy as well as neurocognitive function. Corticosteroids such as dexamethasone can be used to decrease fluid accumulation (edema) around the tumor but are usually only administered after definitive diagnosis before initiation of chemotherapy as they can decrease diagnostic accuracy by altering the tumor. Anticonvulsants are prescribed for patients who develop seizures. Highly active antiretroviral therapy (HAART) should be initiated or optimized in HIV-positive patients.
The treatment of relapsing primary CNS lymphoma is based on the characteristics of the patient and on the response of previous treatment. Chemotherapy can be considered again especially if there was a prolonged durable response to initial therapy. High-dose chemotherapy can also be combined with autologous stem cell transplant, especially in younger patients if this has not been used in the first-line setting. Whole-brain radiation can be considered in patients that have not previously received such treatment. Targeted drugs like ibrutinib and lenalidomide can be considered as they are included in the National Comprehensive Cancer Network (NCCN) guidelines. T-cell immunotherapy targeting EBV-infected B-cells can be considered in patients with EBV-positive post-transplant lymphoproliferative disorder.
For additional information please see the National Cancer Institute information: https://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq
Therapy for primary central nervous system lymphoma is a very active and constantly evolving field of medical research. Multiple molecular pathways involved in the development of primary CNS lymphoma are being targeted by medications tested in clinical trials. There is also an increase in the number of trials with immunotherapies including CAR (chimeric antigen receptor) T-cell therapy.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Toll-free: (800) 411-1222
TTY: (866) 411-1010
Email: [email protected]
Some current clinical trials also are posted on the following page on the NORD website:
https://rarediseases.org/living-with-a-rare-disease/find-clinical-trials/
For information about clinical trials sponsored by private sources, contact:
https://www.centerwatch.com/
For information about clinical trials conducted in Europe, contact:
https://www.clinicaltrialsregister.eu/
JOURNAL ARTICLES
Cai Q, Fang Y, Young KH. Primary central nervous system lymphoma: molecular pathogenesis and advances in treatment. Transl Oncol 2019;12:523-38.
Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol 2019;21:296-305.
Grommes C, Nayak L, Tun HW, Batchelor TT. Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro Oncol 2019;21:306-13.
Labak CM, Holdhoff M, Bettegowda C, et al. Surgical resection for primary central nervous system lymphoma: A systematic review. World Neurosurg 2019.
Brandsma D, Bromberg JEC. Primary CNS lymphoma in HIV infection. Handb Clin Neurol 2018;152:177-86.
Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol 2017;35:2410-8.
Hoang-Xuan K, Bessell E, Bromberg J, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 2015;16:e322-32.
Abla O, Weitzman S, Blay JY, et al. Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Clin Cancer Res 2011;17:346-52.
Bayraktar S, Bayraktar UD, Ramos JC, Stefanovic A, Lossos IS. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol 2011;101:257-65.
Ferreri AJ. How I treat primary CNS lymphoma. Blood 2011;118:510-22.
Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 2011;105:1414-8.
Bhagavathi S, Wilson JD. Primary central nervous system lymphoma. Arch Pathol Lab Med 2008;132:1830-4.
Hochberg FH, Baehring JM, Hochberg EP. Primary CNS lymphoma. Nat Clin Pract Neurol 2007;3:24-35.
Rubenstein JL, Fridlyand J, Shen A, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood 2006;107:3716-23.
INTERNET
Nayak L and Batchelor T. Treatment and prognosis of primary central nervous system lymphoma. UpToDate. Last updated:12/19/2023. https://www.uptodate.com/contents/treatment-and-prognosis-of-primary-central-nervous-system-lymphoma Accessed April 29, 2024.
Nayak L and Batchelor T. Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma. UpToDate. Last updated:2/23/2023. https://www.uptodate.com/contents/clinical-presentation-pathologic-features-and-diagnosis-of-primary-central-nervous-system-lymphoma Accessed April 29, 2024.
Brook I. Brain Abscess Differential Diagnoses. Medscape. Last updated 3/2/2021.
https://reference.medscape.com/article/212946-differential Accessed April 29, 2024.
Gandhi RT. Toxoplasmosis in HIV-infected individuals. UpToDate. Last updated:3/31/2023. https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients Accessed April 29, 2024.
Kaplan LD and Rubenstein JL. AIDS-related lymphomas: Primary central nervous system lymphoma. UptoDate. Last updated:5/19/2023. https://www.uptodate.com/contents/aids-related-lymphomas-primary-central-nervous-system-lymphoma Accessed April 29, 2024.
Primary central nervous system lymphoma. Genetic and Rare Diseases Information Center. https://rarediseases.info.nih.gov/diseases/9318/primary-central-nervous-system-lymphoma Accessed April 29, 2024.
Primary central nervous system lymphoma, Orphanet. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=46135 Accessed April 29, 2024.
Primary CNS Lymphoma Treatment. National Cancer Institute. Last updated: May 25, 2023. Primary CNS Lymphoma Treatment – NCI (cancer.gov) Accessed April 29, 2024.
Huang H.CNS Toxoplasmosis in HIV. Medscape. Last updated:12/5/2022. https://emedicine.medscape.com/article/1167298-overview#a4 Accessed April 29, 2024.
NORD strives to open new assistance programs as funding allows. If we don’t have a program for you now, please continue to check back with us.
NORD and MedicAlert Foundation have teamed up on a new program to provide protection to rare disease patients in emergency situations.
Learn more https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/Ensuring that patients and caregivers are armed with the tools they need to live their best lives while managing their rare condition is a vital part of NORD’s mission.
Learn more https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/This first-of-its-kind assistance program is designed for caregivers of a child or adult diagnosed with a rare disorder.
Learn more https://rarediseases.org/patient-assistance-programs/caregiver-respite/The information provided on this page is for informational purposes only. The National Organization for Rare Disorders (NORD) does not endorse the information presented. The content has been gathered in partnership with the MONDO Disease Ontology. Please consult with a healthcare professional for medical advice and treatment.
The Genetic and Rare Diseases Information Center (GARD) has information and resources for patients, caregivers, and families that may be helpful before and after diagnosis of this condition. GARD is a program of the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
View reportOrphanet has a summary about this condition that may include information on the diagnosis, care, and treatment as well as other resources. Some of the information and resources are available in languages other than English. The summary may include medical terms, so we encourage you to share and discuss this information with your doctor. Orphanet is the French National Institute for Health and Medical Research and the Health Programme of the European Union.
View report